Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Shigella flexneri 2a O-specific polysaccharide (O-PS) is a key component of the bacterium’s outer membrane lipopolysaccharide (LPS). It serves as the major surface antigen and is critical for serotype determination, immune recognition, and vaccine development. The O-PS consists of repeating oligosaccharide units that form the hydrophilic outermost layer of LPS, playing a central role in host-pathogen interactions and protection against environmental stress. It is a branched pentasaccharide with three L-rhamnose residues, one N-acetylglucosamine residue, and one α-D-glucose residue branching from RhaI. Antibodies targeting this polysaccharide confer protection against homologous strains. Synthetic oligosaccharides mimicking two or more consecutive pentasaccharide repeat units are required for optimal antibody recognition and mimicry of natural epitopes—important for vaccine design. Used in conjugate vaccines to enhance immunogenicity in humans.
Target of antibodies; glycoconjugate vaccines stimulate antibody production against the polysaccharide
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Shigella flexneri 2a O-specific Polysaccharide.